Purpose: To investigate long-term visual results of treatment with anti-vascular endothelial growth factor (VEGF) agents for neovascular age-related macular degeneration (nAMD) following a treat-and-extend regimen. Methods: Retrospective review of 155 patients who initiated treatment with bevacizumab for nAMD in one eye. At the final 8-year visit, 40 patients (26%) remained for follow-up. Mean change in best-corrected visual acuity (BCVA) was calculated compared to baseline values. Results: Mean BCVA improved significantly from baseline during the first year of treatment, with À0.11 logMAR units equivalent to 6.1 approximate Early Treatment Diabetic Retinopathy Study (approxETDRS) letters (p = <0.001). Mean BCVA was still significantly improved after 4 years of treatment for the entire group of patients and after 6 years of treatment for the subgroup of 40 patients who remained at the final 8-year visit. Thereafter, BCVA gradually declined and at 8 years, there was a mean change of 0.05 logMAR units equivalent to 2.1 approxETDRS letters below baseline (p = 0.530). Mean number of injections during the first year was 6.1 AE 2.8 and during year 8 was 5.4 AE 3.5. At 5 years, fundus autofluorescence showed some degree of macular atrophy in all eyes. At the final 8-year visit, 87.5% of the eyes had stable neovascular lesions with no fluid on optical coherence tomography (OCT). Conclusion: In an everyday clinical setting, treatment of nAMD patients with a treat-and-extend modality provided improvement and stability of vision for several years. After 8 years of follow-up, there was a decline in visual acuity (VA) that could be explained by macular atrophic development.
Introduction
Neovascular age-related macular degeneration (nAMD) has been a common cause of irreversible vision loss in elderly patients (Bloch et al. 2012; Erke et al. 2012) . Treatment with VEGF medications given as intravitreal injections has dramatically reduced the incidence of blindness from this debilitating disease. Pivotal randomized clinical trials demonstrated excellent visual gain after 2 years of monthly treatment with ranibizumab (Rosenfeld et al. 2006; Brown et al. 2009 ). In clinical practice, monthly visits pose a challenge to elderly patients and overloaded healthcare systems, potentially resulting in delays and undertreatment. Other regimens have later been explored with the purpose of reducing the frequency of visits and treatments. According to the pro re nata (PRN) modality, injections are given only when signs of recurrent disease are observed (Lalwani et al. 2009; Martin et al. 2012) . However, to avoid recurrences or incidents of macular haemorrhage that might result in vision loss, patients need to be monitored on a monthly basis.
The aim of a treat-and-extend regimen is to gradually increase treatment intervals while avoiding potential recurrences. In the event of a recurrence, treatment intervals are reduced until signs of active disease have disappeared. Prospective randomized clinical trials have shown good visual results with a prespecified treatment protocol (Wykoff et al. 2015; Berg et al. 2016) . In clinical practice, retreatment decisions are usually individualized based on the severity of the recurrence. It is therefore of interest to explore whether the favourable results in prospective trials can be maintained in an everyday clinical setting over an extended period of time.
In this retrospective cohort study, patients were treated according to a treat-and-extend modality over a period of 8 years at the Department of Ophthalmology, Oslo University Hospital, Oslo, Norway. The primary objective was to demonstrate long-term visual results after treatment of nAMD with intravitreal anti-VEGF agents and to show potential differences between choroidal neovascularization (CNV) subtypes. Secondary objectives of this retrospective analysis were to investigate causes of interrupted patient follow-up and to analyse anatomical outcomes after 8 years of treatment.
Materials and Methods
This retrospective cohort study was approved by the Norwegian Regional Committees for Medical and Health Research Ethics and was performed according to the tenets of the Declaration of Helsinki.
Patients and data collection
A retrospective review of patient medical records was performed on a consecutive series of 155 patients with newly diagnosed nAMD in one eye between 1 January 2007 and 31 December 2007. Patients were treated and followed up for 8 years until 28 February 2016, with 40 patients remaining at the final 8-year visit.
Inclusion criteria were patients more than 50 years of age with previously untreated nAMD in one eye where treatment was initiated with bevacizumab. Best-corrected visual acuity (BCVA) ranged from 20/20 to 2/200 as measured on a Snellen visual acuity chart. Eyes with macular haemorrhage, fibrosis and geographic atrophy were not excluded.
Exclusion criteria were previous treatment with pegaptanib, ranibizumab, intravitreal steroids or photodynamic therapy (PDT). Eyes with CNV secondary to other macular diseases, such as degenerative myopia or inflammatory eye disease, were excluded.
The diagnosis was confirmed with fluorescein angiography (FA), OCT and by clinical examination. Fundus photography and FA were performed with a Zeiss fundus camera (Carl Zeiss Meditec AG, Jena, Germany). All baseline OCT examinations were performed with a Stratus OCT (Carl Zeiss Meditec AG), while all OCT examinations from 2012 until the last follow-up were performed with a RS-3000 OCT (NIDEK CO., LTD., Gamagori, Japan). Fundus autofluorescence (FAF) examinations were performed with an Optos fundus camera (Optos plc, Dunfermline, UK). Data regarding age, BCVA, type of anti-VEGF agent, number of intravitreal injections and reasons for discontinued follow-up were collected. Subtypes of nAMD were determined from baseline FA by the first author. All baseline OCT examinations were reviewed to confirm the diagnosis of active CNV. The introduction of high-speed scanning OCT technology has led to a newer classification based on both FA examinations and anatomical presentation on OCT imaging (Freund et al. 2010 ). This more advanced OCT technology was not available at the time of baseline, and the less precise visualization of the membrane complex with time-domain OCT was not detailed enough to use the newer classification. Membrane activity status at the last patient visit was collected from patient medical records, and OCT examinations were reviewed by the first author.
Treatment design
Patients received intravitreal injections of either bevacizumab 1.25 mg, ranibizumab 0.5 mg or aflibercept 2.0 mg in 0.05 ml volume. The drugs were acquired commercially. Each syringe was filled directly from the vial by the treating ophthalmologist in an aseptic setting. Prior to injection, standard topical anaesthesia and 5% povidoneiodine solution were applied. Injections were performed 3.5-4.0 mm posterior to the limbus.
Patients initially received monthly intravitreal injections until there were no signs of active nAMD. The treatment intervals were thereafter extended by 2 weeks at a time, typically up to a maximum of 12 weeks. When stability was obtained after reaching a 12-week interval for a prolonged period, patients were either observed without treatment or received maintenance therapy every 12-16 weeks. If examination showed any sign of recurrent disease, the treatment intervals were shortened at the discretion of the treating ophthalmologist, meaning that the intervals could be shortened by 2 weeks at a time when there were signs of discrete recurrences. In the event of more pronounced recurrences, particularly combined with macular haemorrhage, the treatment interval was usually reduced to 4 weeks immediately. Recurrent or active disease was defined as any fluid on OCT, new or persistent haemorrhage or signs of leakage on FA.
All patients were treated with bevacizumab during the study's first year. During the second year, all patients were switched from bevacizumab to ranibizumab treatment in accordance with directives from the Norwegian health authorities, stating that an approved medication should be used for the treatment of nAMD. After further discussion between health authorities and Oslo University Hospital, it was decided that off-label treatment with bevacizumab for nAMD was permissible. Patients were then switched back and treated with bevacizumab from the third year of the study. Starting with year 3, when there was residual fluid on OCT examination despite treatment every 4 weeks, switching to ranibizumab was allowed at the discretion of the treating ophthalmologist. It was also possible to switch to aflibercept from year 6, when the medication became approved and available in Norway for the treatment of nAMD. Any other treatment than anti-VEGF agents for nAMD, such as PDT or epiretinal brachytherapy, resulted in the removal of the patient from the study. Photodynamic therapy (PDT) or epiretinal brachytherapy was performed when there was residual fluid as measured on OCT after treatment failure with all intravitreal anti-VEGF medications available on the market.
Retrospective reviews usually convert Snellen visual acuity measurements to logarithm of the minimum angle of resolution (logMAR) units for statistical calculations. As logMAR units might not be intuitively interpretable by clinicians, conversion of Snellen visual acuity fractions to approxETDRS letter scores was proposed by Gregori et al. (2010) as an alternative method of analysing Snellen visual acuity measurements. In this study, Snellen visual acuity measurements were converted to both logMAR units and approxETDRS letters to facilitate comparison.
Statistical analysis
There is a linear relationship between true ETDRS letter scores, approxETDRS letter scores and logMAR units. Snellen visual acuity scores were converted by the formula 85 + 50 9 log (Snellen fractions) to approxETDRS letter scores (Gregori et al. 2010) . Snellen fractions equivalent to 2/200 could not be calculated with this formula and were therefore converted to an approx-ETDRS letter score of 2. Visual acuity (VA) scores in this study were converted to logMAR and approxETDRS letter units for statistical analysis, and outcomes were presented in both log-MAR and approxETDRS.
The mean BCVA change from baseline was calculated based on data from the last examination before the switch from bevacizumab to ranibizumab treatment and the first examination after the switch from ranibizumab back to bevacizumab treatment. The mean difference in BCVA was thereafter presented yearly. The mean scores were compared within the group using paired t-test. Both 95% confidence intervals and p-values were presented for approxETDRS scores.
Continuous variables were presented as means and standard deviations, and categorical values were presented as percentages.
Statistical calculations were performed with SPSS software version 22 (SPSS, Inc., Chicago, IL, USA).
Results

Patient characteristics
The analysis included 155 patients, 76% women and 24% men, with a mean age of 80.2 AE 8.0 years. Neovascular agerelated macular degeneration (nAMD) lesions were classified as follows: 45.2% occult CNV, 12.3% classic CNV, 22.6% retinal angiomatous proliferation (RAP), 12.9% mixed occult and classic CNV, 2.5% polypoidal choroidal vasculopathy (PCV) and 4.5% with a subretinal haemorrhage covering more than 50% of the neovascular lesion.
At 8 years, 40 (26%) patients remained for follow-up. The distribution of CNV subtypes among these patients was as follows: 45% occult CNV, 20% classic CNV, 22.5% RAP and 12.5% mixed classic and occult CNV.
During the study, cataract surgery was performed on 15 of 155 eyes (9.7%).
Visual acuity
At baseline, mean BCVA for the entire cohort of 155 patients was 0.58 AE 0.34 logMAR units equivalent to 56.1 AE 16.8 approxETDRS letters. After approximately 1 year (14.1 AE 6.8 months) of treatment with bevacizumab, there was a statistically significant increase in BCVA from baseline, with À0.11 log-MAR units corresponding to 6.1 approxETDRS letters (95% CI of mean difference, 3.1-9.0 approx-ETDRS letters; p = <0.001). All patients were then switched to ranibizumab treatment for a period of approximately 1 year (10.9 AE 4.6 months), with an increase at year 2 in mean BCVA of À0.17 logMAR units corresponding to 8.7 approxETDRS letters (95% CI of mean difference, 4.7-12.7 approxETDRS letters; p = <0.001).
There was a small difference in mean BCVA that was not statistically significant after treatment switch from bevacizumab to ranibizumab, with À1.3 approxETDRS letters (p = 0.267). At 3 years, 1 year after switching back to bevacizumab, there was a statistically significant improvement in BCVA compared to baseline, with À0.16 logMAR units equivalent to 8.3 approxETDRS letters (95% CI of mean difference, 4.0-12.6 approxETDRS letters; p < 0.001). At 4 years, the mean increase in BCVA from baseline was still statistically significant, with À0.15 logMAR units corresponding to 7.4 approxETDRS letters (95% CI of mean difference, 3.3-11.4 approxETDRS letters; p = <0.001). After 5 years of treatment, there was a slight increase in BCVA from baseline that was no longer statistically significant, with À0.06 logMAR units equivalent to 3.4 approxETDRS letters (95% CI of mean difference, À1.8 to 8.5 approxETDRS letters; p = 0.194). This was maintained at year 6, with À0.04 logMAR units equivalent to 2.5 approx-ETDRS letters (95% CI of mean difference, À2.3 to 7.2 approxETDRS letters; p = 0.305). At 7 years, there was a drop in BCVA below baseline that was not statistically significant, with 0.08 logMAR units equivalent to À2.9 approxETDRS letters (95% CI of mean difference, À9.3 to 3.5; p = 0.364). This difference compared to baseline remained after 8 years of follow-up, with 0.05 logMAR units equivalent to À2.1 approxETDRS letters (95% CI of mean difference, À8.9 to 4.7; p = 0.530; Fig. 1 ).
The subgroup of 40 patients who completed the 8-year follow-up had a baseline mean BCVA of 0.45 AE 0.30 logMAR units equivalent to 62.6 AE 14.8 approxETDRS letters. After approximately 1 year (14.1 AE 6.8 months) of treatment with bevacizumab, there was a statistically significant visual increase from baseline, with 8.6 approxETDRS letters (95% CI of mean difference, 3.9-13.4 approxETDRS letters; p = 0.001). At 2 years, after approximately 1 year of treatment with ranibizumab (10.9 AE 4.6 months), there was a mean increase in BCVA from baseline of 10.1 approx-ETDRS letters (95% CI of mean difference, 5.7-14.5 approxETDRS letters; p = <0.001). There was a small difference in mean BCVA that was not statistically significant after treatment switch from bevacizumab to ranibizumab, with +1.1 approxETDRS letters (p = 0.343). At 3 years, 1 year after switching back to bevacizumab, the visual improvement was unchanged, with 8.6 approxETDRS letters (95% CI of mean difference, 3.8-13.4 approx-ETDRS letters; p = 0.001). After 4, 5 and 6 years of treatment, the mean increase in BCVA from baseline was still statistically significant, with 8.6 approxETDRS letters (95% CI of mean difference, 3.7-13.4 approxETDRS letters; p = 0.001), 8.0 approxETDRS letters (95% CI of mean difference, 3.1-12.8 approxETDRS letters; p = 0.002) and 5.2 approxETDRS letters (95% CI of mean difference, 0.3-10.2; p = 0.038), respectively. At 7 years, there was a drop in BCVA below baseline that was not statistically significant, with À0.9 approxETDRS letters (95% CI of mean difference, À7.8 to 6.1; p = 0.800). This difference compared to baseline remained after 8 years of follow-up, with À2.1 approxETDRS letters (95% CI of mean difference, À8.9 to 4.7; p = 0.530; Fig. 2) .
At the final 8-year follow-up, the remaining 40 patients had a mean BCVA of 0.50 AE 0.41 logMAR units equivalent to 60.4 AE 18.8 approx-ETDRS letters. Of these, 18 (45%) had BCVA 20/40 or better, while five (12.5%) had BCVA 20/200 or worse.
Mean BCVA change compared to baseline for different subtypes of CNV at 8 years was as follows: +0,1 approx-ETDRS letters (95% CI of mean difference, À13.3 to 13.4; p = 0.993) for occult CNV, À6.1 approxETDRS letters (95% CI of mean difference, À11.8 to À0.5; p = 0.038) for classic CNV, À6.9 approxETDRS letters (95% CI of mean difference, À22.8 to 9.0; p = 0.347) for RAP and +5.0 approxETDRS letters (95% CI of mean difference, À12.5 to 22.5; p = 0.472) for mixed CNV (Fig. 3) .
Secondary end-points
Over the course of 8 years, 74.2% of the patients were withdrawn from the study. The most common reason for discontinued follow-up was inactive neovascular lesion without treatment indication with BCVA 20/200 or better, representing 21.3% of the patients. Once the neovascular lesion was determined to be inactive, with no fluid on OCT, these patients were observed for a mean time of 12.4 AE 10.4 months before they were returned to the referring ophthalmologist for further followup. Best-corrected visual acuity (BCVA) lower than 20/200 resulted in discontinued follow-up in 9.0% of the patients, while the percentage due to death, general health issues or eye disease other than AMD was 24.5%. The percentage of patients who discontinued follow-up due to relocation or at their own request was 5.8%. Withdrawal due to treatment with PDT and epiretinal brachytherapy represented 13.6% of the patients in the study (Table 1) .
Photodynamic therapy (PDT) or epiretinal brachytherapy was performed when there was disease activity on examination with fluid on OCT after treatment failure with all available intravitreal anti-VEGF medications. Throughout the study, 17 eyes were treated with PDT of which 11 eyes received treatment during the first year, one eye during year 2, three eyes during year 3, one eye during year 7 and one eye during year 8. Of four eyes treated with epiretinal brachytherapy, one eye received treatment during year 4 and three eyes during year 5.
All patients were treated with bevacizumab during the study's first year. During the second year, all patients were switched to ranibizumab treatment. Patients were then switched back and treated with bevacizumab. Treatment switch to another anti-VEGF medication thereafter was performed mainly due to active macular nAMD lesions in eyes despite monthly treatment with the current anti-VEGF medication. Starting with year 3, 14 eyes were switched to ranibizumab. Aflibercept became available on the market from year 6, after which 16 eyes were switched from bevacizumab or ranibizumab to aflibercept treatment.
The mean yearly number of bevacizumab injections for the entire group of 155 patients during the first year was 6.1 AE 2.8 over 14.1 AE 6.8 months. At year 2, after 10.9 AE 4.6 months of treatment with ranibizumab, the mean yearly number of injections was 6.8 AE 3.2. After treatment switch back to bevacizumab, the mean number of injections during year 3 was 6.3 AE 3.4. Thereafter, the mean number of yearly anti-VEGF treatments was as follows: 6.2 AE 3.8 injections during year 4, 6.5 AE 3.6 injections during year 5, 7.0 AE 3.9 injections during year 6, 5.6 AE 3.6 injections during year 7 and 5.4 AE 3.5 injections during the final 8-year follow-up.
The mean yearly number of injections for 40 patients who completed the 8-year follow-up was 6.1 AE 2.4 over the first 14.1 AE 2.4 months. At year 2, after 10.9 AE 4.6 months of treatment with ranibizumab, the mean yearly number of injections was 6.7 AE 2.7. After treatment switch back to bevacizumab during year 3, the mean number of injections was 6.4 AE 3.3. Thereafter, the mean number of yearly anti-VEGF treatments was as follows: 6.0 AE 3.7 injections during year 4, 6.6 AE 3.5 injections during year 5, 7.1 AE 3.7 injections during year 6, 6.1 AE 3.6 injections during year 7 and 5.4 AE 3.5 injections during the final 8-year follow-up.
The mean central retinal thickness (CRT) at baseline was 286 AE 80.2 lm. Optical coherence tomography (OCT) readings from baseline were acquired for 149 of 155 eyes. At 5 years, 62 eyes remained for follow-up. The mean CRT was 242 AE 43.9 lm, and there was a statistically significant reduction in mean CRT compared to baseline with 38.7 lm (95% CI of mean difference, 16.4-61.0 lm; p = 0.001). No fluid was detected on OCT in 32 (51.6%) eyes. At the final 8-year follow-up, the mean CRT for the remaining 40 eyes was 221 AE 45.3. There was a statistically significant reduction in CRT compared to baseline, with 61.9 lm (95% CI of mean difference, 32.6-91.2 lm; p = <0.001). No fluid was detected on OCT in 35 (87.5%) eyes.
After 5 years of follow-up, FAF was performed on 59 of 62 eyes. Some degree of macular atrophy was present in all 59 eyes. Atrophy involving the central part of the macula was present in 32 (54.2%) eyes, and in 16 (27.1%) eyes, the macular atrophy was larger than 1 disc area.
After 8 years of follow-up, 32 patients (80%) were followed according to a treat-and-extend modality, with a mean treatment interval of 8.3 AE 3.3 weeks, while eight patients (20%) were observed without treatment due to stable lesions after reaching a maximum interval of 12 weeks.
Discussion
Intravitreal anti-VEGF injections have been proven to be an effective treatment for nAMD in randomized multicenter studies, but most of these studies were not designed to follow study patients for more than 2 years. In this retrospective treat-and-extend study, patients were followed for up to 8 years in an everyday clinical setting. Best-corrected visual acuity (BCVA) for the entire cohort improved significantly from baseline during the first 4 years, with a maximum increase of 8.7 approxETDRS letters at 2 years. Thereafter, there was a continuous visual decline to a level below baseline. The results were similar when analysing the visual outcome for the subgroup of patients who completed the 8-year follow-up but with an additional period of significantly improved vision until year 6. A treatment switch from bevacizumab to ranibizumab for approximately 1 year did not result in any significant visual change.
After 8 years of follow-up, there was a non-significant loss of 2.1 approx-ETDRS letters compared to baseline. In the recently published Comparison of Age-related Macular Degeneration Treatment Trials (CATT) Follow-up Study, 5-year outcomes demonstrated Occult CNV (n = 18), classic CNV (n = 8), RAP (n = 9), mixed CNV (n = 5). BCVA = bestcorrected visual acuity, CNVM = choroidal neovascular membrane, ETDRS = Early Treatment Diabetic Retinopathy Study, n = number of eyes with CNV subtype, RAP = retinal angiomatous proliferation. a decrease in mean BCVA with 3 ETDRS letters below baseline . The SEVEN-UP study assessed 7-to 8-year outcomes in patients who had been treated in the MARINA and ANCHOR studies (Rofagha et al. 2013 ). Compared to baseline measurements, the overall BCVA declined by 8.6 ETDRS letters. Long-time results from several trials highlight the challenge to preserve vision gained over the first years of intravitreal anti-VEGF treatment. Nevertheless, the benefit of anti-VEGF treatment for nAMD is indisputable. The devastating impact on vision from untreated nAMD was shown by the MARINA trial, where BCVA was reduced by 10.4 ETDRS letters below baseline over a period of 2 years in sham-treated patients (Rosenfeld et al. 2006) .
Causes of long-term decrease in vision seem to be related to several factors such as the number of injections, residual macular oedema and development of macular atrophy or scarring. A sufficient number of intravitreal injections are known to be an important factor in obtaining good visual results (Martin et al. 2012 ). An increased number of treatments have also been associated with progression of geographic atrophy. Results from the CATT trial demonstrated a higher risk of developing geographic atrophy over 2 years in eyes treated monthly compared to eyes treated PRN (Grunwald et al. , 2015 . In contrast, subjects in the SEVEN-UP trial received an average of only 1.6 yearly injections during the last 3.3 years of the study and after a mean follow-up of 7.3 years, macular atrophy was found in 98% of the eyes (Rofagha et al. 2013) . Munk et al. found macular atrophy in 73.5% of subjects treated with a real-life treatand-extend modality, where patients received an average of 8 yearly injections after a mean of 6.2 years. The lower prevalence of macular atrophy compared to the SEVEN-UP study was explained by a higher number of treatments and thereby suggesting undertreatment rather than overtreatment as a possible cause of formation and growth of macular atrophy (Munk et al. 2016 ).
In the current study, patients received between six and seven injections annually during the first 6 years, while the average number of treatments during the last year of the study was between 5 and 6. After 5 years of treatment, all eyes had some degree of macular atrophy detected on FAF and in more than half of the eyes, the atrophy involved the central part of the macula. There was fluid detected on OCT in approximately half of the eyes at 5 years. Eyes with residual oedema were switched to aflibercept from year 6, when the medication became available on the market. The following year, there was, however, a pronounced drop in mean BCVA to a level below baseline that remained at the last follow-up. Even though there was no fluid detected on OCT in a large majority (87.5%) of the eyes at the final 8-year visit, the intensified treatment did not improve the final visual outcome. Accordingly, the visual decline was interpreted to be caused by the development of macular atrophy.
The negative visual impact over time in this study was more pronounced for classic and RAP lesions compared to occult and mixed CNV subtypes. At 8 years, eyes with classic lesions had lost more than 6 approxETDRS letters below baseline. In comparison, occult CNV lesions had a mean improvement in BCVA slightly over baseline and mixed lesions had an improvement of 5 approxETDRS letters compared to baseline. While RAP lesions were less likely to develop scarring, classic lesions were a predictor for scarring at 2 years in the CATT subanalysis (Daniel et al. , 2016 . Retinal angiomatous proliferation (RAP) lesions were also more likely to have geographic atrophy at 1 and 2 years compared to other types of CNV . The increased development of geographic atrophy for RAP lesions has been related to geographic atrophy in the fellow eye, baseline subfoveal thinning and reticular pseudodrusen (Cho et al. 2015) . Although the number of eyes in each group of CNV subtypes in our study was small, the reason for the worse visual outcomes for RAP and classic lesions might be explained by atrophy and scarring.
This study has limitations due to its retrospective nature. After 8 years of follow-up, 74% of the patients were discontinued from the study, of which more than half within the first 2 years of treatment. The study included all patients who initiated treatment with bevacizumab during the year 2007, meaning that eyes with subretinal fibrosis or macular haemorrhage at baseline were not excluded. As eyes with poor prognosis presumably terminate treatment early, the remaining patients could therefore have represented a selection with better BCVA. Furthermore, although patients were followed using a treat-and-extend principle, the choice of intervals and drugs used for each individual was at the discretion of the treating ophthalmologist. A strict protocol that would be mandated in a randomized clinical trial is difficult to apply in a long-term reallife clinical setting. Even so, 80% of the remaining patients at 8 years were extended up to and treated with a mean interval of 8.3 weeks, with a reduced burden on patients and the ophthalmological department compared to monthly monitoring. The single most common reason for deviating from the treat-and-extend modality was a stable CNV lesion with BCVA 20/200 or better. After having extended the treatment and control interval up to 12 weeks, 21% of the patients were observed without treatment for more than a year without recurrences before they were returned to the referring ophthalmologist. Photodynamic therapy (PDT) and brachytherapy were the second most common reason for discontinued follow-up (14%). The indication for these treatments was residual fluid detected on OCT after all available anti-VEGF medications had been tried. Most PDT treatments (80%) were performed during the first 2 years of the study, before aflibercept had been approved for the treatment of nAMD.
In conclusion, treatment following a treat-and-extend modality increased VA for several years. After 8 years of treatment, there was a visual reduction to baseline level that was interpreted to be caused by the development of macular atrophy. When considering the rapid and poor visual outcome caused by untreated nAMD, the results should be interpreted positively in this cohort of elderly patients. The development of macular atrophy and its relationship to the number of anti-VEGF treatments, treatment modality and residual macular fluid are complex and need to be further investigated in randomized clinical trials.
